[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"analgesics-opioid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:analgesics-opioid":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,51,70,108,134,165,189,223],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100644228","quality-of-recovery-15-after-opioid-free-versus-opioid-based-general-anesthesia-in-major-urological-surgery-100644228",false,"NCT07665463","Quality of Recovery-15 After Opioid-free Versus Opioid-based General Anesthesia in Major Urological Surgery","Uality of Recovery-15 After Opioid-free Versus Opioid-based General Anesthesia in Patients Undergoing Elective Major Urological Surgery: A Randomized Controlled Trial","QoR-OFA-URO","Inclusion Criteria:\n\n* Adults aged 18 to 75 years.\n* Scheduled for elective major urological surgery under general anesthesia, including laparoscopic or robotic nephrectomy, laparoscopic or robotic prostatectomy, or laparoscopic or robotic cystectomy.\n* Ability to operate a patient-controlled analgesia pump postoperatively.\n* Ability to understand and use the Numeric Rating Scale for pain assessment.\n* Ability to understand and complete the Quality of Recovery-15 questionnaire.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Patient refusal to participate.\n* Inability to operate the patient-controlled analgesia pump.\n* Inability to understand the Numeric Rating Scale for pain assessment.\n* Inability to understand or complete the Quality of Recovery-15 questionnaire.\n* Known hypersensitivity to any of the study drugs, including anesthetics, ketamine, dexmedetomidine, lidocaine, ropivacaine, oxycodone, metamizole, paracetamol, or ibuprofen.\n* Second- or third-degree atrioventricular block.\n* Symptomatic bradycardia.\n* Chronic opioid use.\n* Contraindication to the planned regional anesthesia technique, including coagulopathy, therapeutic anticoagulation, or infection at the puncture site.","ALL","18 Years","75 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"NA","This randomized controlled trial evaluates postoperative quality of recovery assessed with the Quality of Recovery-15 questionnaire in adult patients undergoing elective major urological surgery under opioid-free versus opioid-based general anesthesia.\n\nOpioid-free anesthesia is a multimodal anesthetic technique that avoids intraoperative opioids by combining non-opioid analgesic and sympatholytic agents such as dexmedetomidine, ketamine, lidocaine, non-steroidal anti-inflammatory drugs, and regional analgesia. Opioid-based general anesthesia in this trial includes intraoperative remifentanil infusion.\n\nParticipants will undergo elective urological surgery, including laparoscopic nephrectomy, robotic nephrectomy, laparoscopic prostatectomy, robotic prostatectomy, laparoscopic cystectomy, or robotic cystectomy.\n\nThe primary objective is to compare patient-reported quality of recovery between the opioid-free anesthesia group and the remifentanil-based anesthesia group using the Quality of Recovery-15 questionnaire. QoR-15 will be assessed before surgery and on postoperative day 7.\n\nSecondary objectives include total postoperative oxycodone dose administered via patient-controlled analgesia during the first 24 hours after surgery, postoperative pain intensity measured using the Numeric Rating Scale at 1, 2, 6, 12, and 24 hours after surgery, incidence of postoperative nausea and vomiting, change in serum creatinine from baseline to postoperative day 1, change in white blood cell count from baseline to postoperative day 1, and the ratio of demanded to delivered PCA boluses.\n\nPre-specified subgroup analyses will compare outcomes according to surgical procedure type: laparoscopic nephrectomy, robotic nephrectomy, laparoscopic prostatectomy, robotic prostatectomy, laparoscopic cystectomy, and robotic cystectomy. Subgroup-by-treatment interaction tests will be performed.\n\nPlanned enrollment is approximately 600 patients, with 300 patients per treatment arm. The primary patient-reported recovery endpoint will be assessed on postoperative day 7, while analgesic, pain, and early postoperative safety outcomes will be assessed during the first 24 hours after surgery.",[28,29,30,31],"Postoperative Recovery","Anesthesia, General","Analgesics, Opioid","Urologic Surgical Procedure",[33,34,35,36,37],"Quality of Recovery-15","QoR-15","Opioid-free anesthesia","Remifentanil","Urological surgery","NOT_YET_RECRUITING","2026-06-18",{"date":41,"type":42},"2026-06-24","ACTUAL",{"date":44,"type":22},"2026-07-01",{"date":46,"type":22},"2027-12-31",{"name":48,"class":49},"Jagiellonian University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":50},"100545310","opioid-free-anesthesia-as-an-alternative-to-general-anesthesia-in-abdominal-surgery-100545310","NCT06380244","Opioid-free Anesthesia as an Alternative to General Anesthesia in Abdominal Surgery","Inclusion Criteria:\n\n* Adults aged 18-75 years scheduled for elective urological surgery under general anesthesia: laparoscopic or robotic nephrectomy, laparoscopic or robotic prostatectomy, or laparoscopic or robotic cystectomy.\n* Ability to operate a patient-controlled analgesia (PCA) pump postoperatively.\n* Ability to understand and use the Numeric Rating Scale (NRS) for pain assessment.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Patient's refusal to participate.\n* Inability to operate the PCA pump.\n* Inability to understand the NRS pain scale.\n* Known hypersensitivity to any of the study drugs (anesthetics, ketamine, dexmedetomidine, ropivacaine, oxycodone, metamizole, paracetamol, ibuprofen).\n* Second- or third-degree atrioventricular block, or symptomatic bradycardia.\n* Chronic opioid use.\n* Contraindication to the planned regional anesthesia technique (e.g. coagulopathy or therapeutic anticoagulation, infection at the puncture site).",{"count":58,"type":22},600,[25],"Opioid-free anesthesia (OFA) is a multimodal technique that eliminates intraoperative opioids by combining dexmedetomidine, ketamine, lidocaine, NSAIDs, and regional analgesia. Growing evidence suggests OFA reduces postoperative opioid consumption, opioid-related adverse effects, and may have favorable oncological implications in cancer surgery.\n\nThis randomized controlled trial compares OFA with opioid-based anesthesia (remifentanil) in patients undergoing elective urological surgery: laparoscopic nephrectomy, robotic nephrectomy, laparoscopic prostatectomy, robotic prostatectomy, laparoscopic cystectomy, and robotic cystectomy.\n\nThe PRIMARY OBJECTIVE is to compare the total postoperative oxycodone dose (mg) administered via patient-controlled analgesia (PCA) during the first 24 hours after surgery between the OFA and remifentanil groups.\n\nSECONDARY OBJECTIVES include: postoperative pain intensity (NRS) at 1, 2, 6, 12, and 24 hours; incidence of postoperative nausea and vomiting (PONV); change in serum creatinine from baseline to postoperative day 1; change in white blood cell (WBC) count from baseline to postoperative day 1; and the ratio of demanded to delivered PCA boluses.\n\nPRE-SPECIFIED SUBGROUP ANALYSES will compare outcomes by surgical procedure type: laparoscopic nephrectomy, robotic nephrectomy, laparoscopic prostatectomy, robotic prostatectomy, laparoscopic cystectomy, and robotic cystectomy. Subgroup-by-treatment interaction tests will be performed and reported as forest plots.\n\nPlanned enrollment: approximately 600 patients (300 per arm). Follow-up: 24 hours postoperatively.",[30,62,29],"Anesthesia, Endotracheal","RECRUITING",{"date":41,"type":42},{"date":66,"type":42},"2024-03-10",{"date":68,"type":22},"2026-12-31",{"name":48,"class":49},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100592516","phase-3-optimizing-pain-treatment-in-children-on-mechanical-ventilation-100592516","NCT06994442","Optimizing Pain Treatment in Children On Mechanical Ventilation","OPTICOM","Inclusion Criteria:\n\n1. At least 2 months of age to 17 years 6 months; AND\n2. Acute Respiratory Failure requiring endotracheal intubation; AND\n3. Opioid infusion planned or started; AND\n4. Expected duration of Invasive Mechanical Ventilation \\> 48 hours\n\nExclusion Criteria:\n\n1. History of allergic-type reaction to either acetaminophen or non-steroidal anti-inflammatory (NSAID) medications; OR\n2. Active peptic ulcer disease, recent gastrointestinal bleeding or perforation, or history of peptic ulcer disease or gastrointestinal bleeding; OR\n3. Expected need for continuous neuromuscular blockade for more than 24 hours following intubation; OR\n4. Requirement for tight temperature control (defined as the requirement for continuous administration of antipyretic medications to prevent secondary injuries associated with fever); OR\n5. Platelet count \\\u003C 100,000\u002Fmicroliter; OR\n6. Known liver disease (defined as pre-existing diagnosis of hepatic insufficiency, or a serum ALT \\> 5 times upper limit of normal or serum total bilirubin \\> 2 times the upper limit of normal, as defined by hospital laboratory standards); OR\n7. Known kidney disease (defined as pre-existing diagnosis of renal insufficiency, or an estimated creatinine clearance \\\u003C 30 mL\u002Fmin\u002Fm2 obtained within the previous 24-hours prior to eligibility, or high risk of renal failure due to volume depletion); OR\n8. Current treatment with extracorporeal therapies (e.g., ECMO, CVVH, plasma exchange); OR\n9. Cardiac bypass surgery within the past 24 hours prior to eligibility; OR\n10. Requirement for the patient to receive lithium, pentoxifylline or probenecid as part of their routine care; OR\n11. Unable to obtain consent and randomize within 12 hours of eligibility, OR\n12. Positive pregnancy test; OR\n13. Coma, Vegetative State, or Brain Death (Pediatric Cerebral Performance Category (PCPC) score of 5 or 6) suspected or confirmed; OR\n14. Cardiac arrest has occurred within 72 hours of eligibility criteria being met; OR\n15. Limitations in care in place at the time of eligibility, or anticipated to be considered during the 5-day study period, OR\n16. Use of high dose NSAIDS within the prior 6 months, OR\n17. Suspected or confirmed cerebrovascular bleeding or hemorrhagic diathesis","2 Months","17 Years",{"count":80,"type":22},644,[82],"PHASE3","In this clinical trial, investigators want to learn more about using non-opioid pain medications for children with acute respiratory failure. Right now, doctors give these children opioids to help with pain while they are on the ventilator, but investigators don't know if this is the best way to manage their pain. Even with strong doses of opioids, more than 90% of these children still feel pain. Other pain medicines, like acetaminophen (also called Tylenol) and ketorolac (also called Toradol), are available but aren't commonly used because we don't know if they help. The goal of this clinical trial is to test if acetaminophen and\u002For ketorolac can improve pain control and reduce the need for stronger pain medications (opioids) in these children.\n\nTo learn more about this, participants will be randomly placed in one of four study treatment groups. This means that a computer will decide by chance which group each participant is in, not the doctors running the study. Each group will receive a combination of intravenous acetaminophen, ketorolac or a harmless substance called a placebo. In this clinical trial, placebos help investigators see if the actual medications (acetaminophen and ketorolac) work better than something that doesn't contain medicine. By comparing participants who get the real medicine with those who get the placebo, investigators can find out if these medications effectively decrease pain.",[85,86,30,87],"Mechanical Ventilation","Pediatric Acute Respiratory Failure","Sedation and Analgesia",[89,90,91,92,93,94,95,96,97],"Acetaminophen","Ketorolac","Non-opioids","Acute Respiratory Failure in Children","Mechanically Ventilated Children in the ICU","Pediatric Delirium","Pain Treatment","opioids","sedation","2026-02-17",{"date":100,"type":42},"2026-02-20",{"date":102,"type":42},"2025-12-29",{"date":104,"type":22},"2029-08-31",{"name":106,"class":49},"Weill Medical College of Cornell University",15,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":133},"100583568","phase-4-comparing-the-safety-and-effectiveness-of-different-doses-of-morphine-administered-in-spinal-anethesia-for-pain-relief-after-hip-replacement-surgery-100583568","NCT06878014","Comparing the Safety and Effectiveness of Different Doses of Morphine Administered in Spinal Anethesia for Pain Relief After Hip Replacement Surgery","Comparison of Safety Profile and Efficacy of Different Doses of Intrathecal Morphine in Total Hip Replacement.","Inclusion Criteria:\n\n* Informed consent to participate in trial\n* Qualification for total hip replacement surgery\n* ASA physical status I-III\n* BMI 19-30\n* Lack of contraindications for drugs and interventions used in trial\n\nExclusion Criteria:\n\n* Incapability to provide informed consent\n* Contraindications for spinal anesthesia\n* Preoperative chronic pain\n* Chronic use of analgesics\n* Obesity (BMI\\>30)\n* Allergies and other contraindications for drugs used in trial\n* Mental or physical incapability to operate PCA syringe pump",{"count":116,"type":22},120,[118],"PHASE4","Pain management after total hip replacement is one of the most important aspects of postoperative care for patients and clinicians alike. One of the most common techniques used in anesthesia for this procedure is spinal anesthesia with concurrent administration of opioids into spinal sac. Addition of opioids not only prolongs the anesthesia but also provides pain relief after the procedure for a limited amount of time. Because of its unique chemical properties morphine provides the longest pain relief amongst currently known opioids lasting up to 24 hours. Unfortunately this beneficial effect is associated with both minor and serious adverse effects, most important of which is respiratory depression.\n\nTo limit this potenitialy fatal adverse effect dosing of morphine must be very precise in order to balance advantages and risks.\n\nThe aim of the study was to assess effectiveness and safety profile of different doses of morphine administered during spinal anesthesia for pain control.",[30,121,122,123],"Anesthesia, Spinal","Total Hip Replacement","Adverse Anesthesia Outcome","2026-02-11",{"date":126,"type":42},"2026-02-12",{"date":128,"type":42},"2025-03-04",{"date":130,"type":22},"2026-06-28",{"name":132,"class":49},"Medical University of Silesia",3,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":23,"phases":143,"briefSummary":144,"conditions":145,"keywords":151,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":50},"100623447","the-effects-of-transversalis-fascia-plane-block-on-opioid-consumption-in-patients-undergoing-hand-assisted-laparoscopic-donor-nephrectomy-a-randomized-controlled-prospective-study-100623447","NCT07396753","The Effects of Transversalis Fascia Plane Block on Opioid Consumption in Patients Undergoing Hand-Assisted Laparoscopic Donor Nephrectomy: A Randomized Controlled Prospective Study","Inclusion Criteria:\n\n* Approved by the transplant committee for living kidney donation\n* Scheduled for hand-assisted laparoscopic donor nephrectomy (HALDN)\n* Able to understand study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Known allergy to any medications used in the study (e.g., local anesthetics, opioids)\n* Chronic opioid use or use of opioid receptor agonists\n* Inability to communicate effectively (e.g., cognitive impairment, language barrier)\n* Chronic organ failure or major organ dysfunction\n* Refusal or inability to provide informed consent\n* Foreign nationality (if follow-up or consent is restricted)\n* American Society of Anesthesiologists (ASA) physical status ≥ III","80 Years",{"count":142,"type":22},50,[25],"This study aims to evaluate whether a regional anesthesia technique called the transversalis fascia plane block (TFPB) can improve pain control after hand-assisted laparoscopic donor nephrectomy (HALDN), a minimally invasive surgery performed in living kidney donors.\n\nAlthough HALDN is less invasive than open surgery, patients often experience significant pain after the operation, mainly due to the surgical incisions in the lower abdomen and trocar entry sites. Poorly controlled pain can delay recovery and increase the need for opioid pain medications, which may cause side effects such as nausea, vomiting, itching, and sedation.\n\nThe transversalis fascia plane block is an ultrasound-guided regional anesthesia technique in which a local anesthetic is injected into a specific tissue plane in the lower abdominal wall. This injection temporarily blocks pain signals from nerves supplying the lower abdomen and groin area. The technique has been shown to reduce pain and opioid use after various lower abdominal surgeries and is considered minimally invasive and safe when performed under ultrasound guidance.\n\nIn this study, patients undergoing HALDN will be randomly assigned to one of two groups. One group will receive standard general anesthesia only, while the other group will receive general anesthesia plus a transversalis fascia plane block using a local anesthetic (bupivacaine). All patients will receive the same standard pain treatment after surgery, including paracetamol and patient-controlled morphine.\n\nThe main goal of the study is to compare the amount of opioid pain medication used during the first 24 hours after surgery between the two groups. Secondary outcomes include pain scores measured using the Numeric Rating Scale (NRS), the frequency of opioid-related side effects, and patient satisfaction with pain control.\n\nThe results of this study may help determine whether adding the transversalis fascia plane block to standard anesthesia can provide better pain relief, reduce opioid consumption, and improve comfort and recovery in living kidney donors.",[146,30,147,148,149,150],"Postoperative Pain","Pain Management","Anesthesia Regional","Living Donors","Nephrectomy,Kidney Donation",[152,153,154,155],"Hand-assisted laparoscopic donor nephrectomy","Transversalis fascia plane block","Regional anesthesia","Opioid consumption","2026-02-02",{"date":158,"type":42},"2026-02-09",{"date":160,"type":42},"2025-07-25",{"date":162,"type":22},"2026-03-03",{"name":164,"class":49},"Koç University",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":171,"sex":17,"minAge":18,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":50},"100553584","asleep-fiberoptic-vs-direct-laryngoscopy-effect-on-hemodynamic-stability-using-opioid-free-anesthesia-induction-100553584","NCT06487988","Asleep Fiberoptic vs Direct Laryngoscopy Effect on Hemodynamic Stability Using Opioid Free Anesthesia Induction","Inclusion Criteria:\n\n* ASA (American Society of Anesthesiologists) physical status I and II\n* Range age of 18-55 years' old\n* Scheduled for elective surgery under general anesthesia.\n\nExclusion Criteria:\n\n* History of cardiovascular diseases.\n* History of lung disease.\n* Hypertensive patient (BP\\> 140\u002F90)\n* Patient taking medications that affect blood pressure and heart rate\n* Morbid obesity (BMI \\>30)\n* Severe GERD\n* Predicted difficult airway (Short TMD \\\u003C6 cm, Upper li bite test grade III, Mallampati score\n\n  \\>III)\n* Neck instability\n* Patient planned to receive rapid sequence intubation\n* Patient refusal to participate\n* History of difficult intubation\u002F ventilation",true,"55 Years",{"count":174,"type":22},90,[25],"The goal of this clinical trial is to compare blood pressure and heart rate between the fiberoptic and direct oral intubation using opioid free anesthesia induction. Secondary objectives include comparing the time needed for intubation and the incidence of postoperative sore throat, hoarseness, and upper airway trauma in adults aging between 18 to 55 years, scheduled for elective surgery under general anesthesia.\n\nThe main question it aims to answer is:\n\nDoes fiberoptic intubation cause less hemodynamic instability than direct oral intubation using opioid free anesthesia induction?",[30,29,178,179],"Heart Rate","Blood Pressure","2025-12-15",{"date":182,"type":42},"2025-12-19",{"date":184,"type":42},"2024-09-11",{"date":186,"type":22},"2026-01-01",{"name":188,"class":49},"American University of Beirut Medical Center",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":197,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":23,"phases":200,"briefSummary":201,"conditions":202,"keywords":208,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":133},"100504026","patient-centred-deprescribing-of-psychotropic-sedative-and-anticholinergic-medication-in-elderly-patients-with-polypharmacy-100504026","NCT05842928","Patient-centred Deprescribing of Psychotropic, Sedative and Anticholinergic Medication in Elderly Patients With Polypharmacy","Patient-centred Deprescribing of Psychotropic, Sedative and Anticholinergic Medication in Elderly Patients With Polypharmacy: a Cluster-randomised Trial","PARTNER","Inclusion Criteria:\n\n* Aged 65 years or older\n* Patient is capable of giving consent\n* GP contact in the quarter prior to inclusion\n* Current use of ≥ 5 drugs, including ≥ 1 PSA-PIM (hypnotics, opioids, gabapentinoids, antipsychotics, antidepressants, anticholinergic urospasmolytics) with a treatment duration of ≥ 6 months\n* Willingness to select a regular pharmacy for the study period\n* Consent to data exchange between GP and community pharmacy\n\nExclusion Criteria:\n\n* Terminal illness (life expectancy \\\u003C 6 months)\n* Current treatment of pain associated with cancer\n* Other serious physical illness or mental distress (e.g. bereavement) that makes participation in the study impossible (according to the GP's assessment)\n* Psychiatric illness or addiction that makes participation in the study impossible (according to the GP's assessment)\n* Unable to meet the requirements of the study (participation in telephone or written questionnaires, visits to the GP practice or community pharmacy, alone or with the help of caregivers for physical infirmity)\n* Current participation in research projects on medication safety or geriatric medicine","65 Years",{"count":199,"type":22},352,[25],"The PARTNER study is a multicentre, two-arm, pragmatic cluster-randomised trial evaluating the impact of a focused and patient-centred cooperation between general practitioners (GPs) and community pharmacists (PARTNER intervention) on reductions in the use of psychotropic, sedative and anticholinergic potentially inappropriate medication (PSA-PIM) compared to a control intervention. The PARTNER intervention comprises (1) education for health care professionals, (2) an interprofessional workshop and case conference, (3) a pharmacy visit with brown bag\u002Fmedication review and patient empowerment, (4) GP practice visit with shared decision making. The control intervention only comprises a pharmacy visit with brown bag review.",[203,204,205,30,206,207],"Deprescriptions","Antidepressive Agents","Antipsychotic Agents","Hypnotics and Sedatives","Cholinergic Antagonists",[209,210,211,212,213],"Polypharmacy","General Practice","Primary Health Care","Pharmacies","Medication Safety","2025-04-30",{"date":216,"type":42},"2025-05-04",{"date":218,"type":42},"2023-03-25",{"date":220,"type":22},"2026-10",{"name":222,"class":49},"Ludwig-Maximilians - University of Munich",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":17,"minAge":230,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":23,"phases":233,"briefSummary":234,"conditions":235,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":242,"leadSponsor":244,"locationsCount":50},"100514986","phase-4-ipack-on-early-pain-scores-after-acl-reconstruction-100514986","NCT05985629","IPACK on Early Pain Scores After ACL Reconstruction","The Effect of IPACK Nerve Blocks on Early ACL Pain Scores","Inclusion Criteria:\n\n* All patients presenting to Dr. John Miller with the Department of Orthopedic Surgery, Sports Medicine Division, at Loyola University Medical Center electing to undergo ACL reconstruction surgery.\n* Patients 16 and over\n* English speaking patients\n* Patients who have the capacity to make their own medical decisions and consent to the study\n\nExclusion Criteria:\n\n* Previous surgery on the operative knee\n* Previous knee infection\n* Chronic opioid use\n* Have a known allergy to local anesthetics\n* Patient using autograft (cadaver) for ACL reconstruction.","16 Years",{"count":232,"type":22},78,[118],"The goal of this clinical trial is to learn whether using an anesthetic technique called IPACK block will control pain after ACL reconstruction surgery. The main questions it aims to answer are:\n\n* if participants who receive the IPACK block prior to ACL reconstruction experience less pain after surgery and at 1 day after surgery\n* if participants who receive the IPACK block prior to ACL reconstruction require less short-term opioid use immediately after surgery and up to one week after surgery.\n\nParticipants will be randomized 1:1 to 1 of 2 groups: Use of IPACK block during ACL reconstruction vs. placebo (a placebo is a look-alike substance that contains no active drug). Neither the participant nor the investigator will know which group the participants has been assigned to.\n\nResearchers will compare self-reported pain scores and short-term opioid use of all study participants.",[236,237,30],"Pain, Postoperative","Anterior Cruciate Ligament Injuries","2023-08-03",{"date":240,"type":42},"2023-08-14",{"date":238,"type":42},{"date":243,"type":22},"2026-08-03",{"name":245,"class":49},"Loyola University"]